Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

NCT03905642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Arikayce™

Sponsor

Insmed Incorporated